Drugs likely to be among the first subject to negotiation include Pfizer’s breast cancer treatment Ibrance and the blood thinner Eliquis, which Pfizer shares with Bristol Myers Squibb. The pharmaceutical industry says the law will result in a loss of profits that will force drugmakers to pull back on developing groundbreaking new treatments., Drugs likely to be among the first subject to negotiation include Pfizer’s breast cancer treatment Ibrance and the blood thinner Eliquis, which Pfizer shares with Bristol Myers Squibb. The pharmaceutical industry says the law will result in a loss of profits that will force drugmakers to pull back on developing groundbreaking new treatments., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way